Avience Biomedicals IPO – Company Analysis
Avience Biomedicals Limited is an ISO-certified healthcare and biotechnology company engaged in the manufacturing, distribution, and export of molecular diagnostic products. The company operates in the biotechnology, genomics, and in-vitro diagnostics (IVD) segments, serving the growing demand for advanced diagnostic solutions in India and international markets.
Over the years, Avience Biomedicals has expanded its product portfolio beyond IVD rapid test kits to include a wide range of medical devices and diagnostic equipment. Its offerings include biochemistry analyzers, serology products, molecular diagnostics solutions, hematology analyzers, reagents, and various medical equipment used across healthcare facilities. The company's focus on innovation and quality enables it to cater to the evolving needs of the healthcare industry.
The company's products are utilized by hospitals, pathology laboratories, microbiology laboratories, diagnostic centers, and research institutions. In addition to manufacturing, Avience Biomedicals is also involved in the distribution and trading of medical devices, strengthening its presence across the healthcare value chain.
The company offers a comprehensive range of diagnostic solutions, including:
Rapid Test Kits
Molecular Diagnostic Products
Biochemistry Reagents and Analyzers
Hematology Analyzers
Serology Products
Medical Equipment and Devices
Avience Biomedicals IPO Details
The Avience Biomedicals IPO will open for subscription on June 18, 2026, and close on June 22, 2026. The basis of allotment is expected to be finalized on June 23, 2026, while refunds and share credit are scheduled for June 24, 2026.
The IPO is a book-built SME issue aggregating ₹30.24 crore and consists entirely of a fresh issue of approximately 14.54 lakh equity shares.
Subject to regulatory approvals and market conditions, the shares are proposed to be listed on the NSE SME platform on June 25, 2026.
The Avience Biomedicals IPO price band has been fixed at ₹196 to ₹208 per equity share.
IPO Timetable (Tentative)
Events | Date |
IPO Opening Date | Jun 18, 2026 |
IPO Closing Date | Jun 22, 2026 |
IPO Allotment Date | Jun 23, 2026 |
Refund Initiation | Jun 24, 2026 |
IPO Listing Date | Jun 25, 2026 |
Company Financials
(Amount in Cr)
Particulars | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
Assets | 66.07 | 56.52 | 34.65 |
Total Income | 41.94 | 45.97 | 24.37 |
Profit After Tax | 5.74 | 7.23 | 2.14 |
EBITDA | 10.34 | 11.41 | 4.08 |
Net Worth | 28.52 | 22.78 | 6.21 |
Reserves and Surplus | 24.49 | 18.75 | 2.93 |
Total Borrowing | 26.73 | 22.16 | 15.13 |
Cash Flows
(Amount in lac)
Net Cash Flow | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
Net Cash Flow Operating Activities | 277.79 | 360.63 | 98.50 |
Net Cash Flow Investing Activities | (903.53) | (880.59) | (402.77) |
Net Cash Flow Financing Activities | 306.74 | 925.37 | 296.72 |
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
Objective of the Issue
Avience Biomedicals Limited intends to utilize the net proceeds from the IPO to support its expansion and operational requirements. The primary objectives of the issue are as follows:
- Capital Expenditure: Approximately ₹15.96 crore will be used to part-finance the establishment of a new manufacturing facility at Industrial Plot No. 70, Sector 28, Medical Device Park, under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh.
- Working Capital Requirements: Around ₹8.25 crore will be allocated towards funding the company's working capital needs to support business growth and day-to-day operations.
- General Corporate Purposes: The remaining funds will be utilized for general corporate purposes, including strengthening the company's overall financial position and supporting future business initiatives.
Listed Peers of Avience Biomedicals Ltd.
No listed peer of a similar size is engaged in the same lines of business as mentioned in the RHP.
Valuation
KPI | Value (Mar 31, 2025) |
RoE | 38.64% |
ROCE | 21.68% |
Debt/Equity | 0.67 |
RoNW | 38.64% |
PAT Margin | 15.86% |
EBITDA Margin | 26.49% |
Price to Book Value | 4.09 |
Evaluation of P/E Ratio
Based on the company's FY 2025 financial performance, it reported an Earnings Per Share (EPS) of ₹19.06. Considering the upper price band of ₹208 per share, the IPO is offered at a Price-to-Earnings (P/E) ratio of 10.91x, indicating the valuation at which investors are subscribing to the issue.
IPO Strengths
Experienced management team with strong industry knowledge and expertise in the biotechnology and diagnostics sector.
Diverse product portfolio including rapid test kits, molecular diagnostics, biochemistry analyzers, hematology analyzers, and medical devices.
Well-established distribution network across India with a growing presence in international markets.
Focus on providing cost-effective and affordable diagnostic solutions to healthcare providers and institutions.
IPO Weaknesses
Dependence on key suppliers for raw materials and critical components may impact operations if supply disruptions occur.
Significant investment in research and development can increase operational costs and affect profitability.
Faces intense competition from established domestic and international players in the diagnostics and healthcare sector.
Subject to stringent regulatory requirements and compliance standards, which may impact business operations and expansion plans.
Avience Biomedicals IPO GMP (Grey Market Premium)
As of June 20, 2026, Avience Biomedicals IPO GMP stands not yet in the grey market. Based on the upper price band of ₹208, the estimated listing price could be around ₹248 per share, indicating a potential premium of approximately 19.23%.
Investors should note that Grey Market Premium (GMP) is an unofficial market indicator and may change frequently based on market sentiment and demand. Therefore, GMP should be considered alongside the company's fundamentals, financial performance, and growth prospects before making an investment decision.
Avience Biomedicals IPO Summary
IPO Opening & Closing Date | 18 Jun, 2026 to 22 Jun, 2026 |
Face Value | Rs. 10 per Share |
Issue Price | Rs. 196 to Rs. 208 per Share. |
Lot Size | 600 Shares |
Issue Size | 14,53,800 Shares (Rs. 30 Cr) |
Offer for Sale | - |
Fresh Issue | 13,71,600 Shares (Rs. 29 Cr) |
Listing at | NSE, SME |
Issue Type | Book build Issue |
Registrar | Skyline Financial Services Pvt. Ltd. |
Avience Biomedicals IPO Lot Size Details
The minimum application size for retail investors is 1 lot consisting of 600 shares, requiring an investment of ₹1,24,800 at the upper price band. Retail investors can apply for a maximum of 2 lots (1,200 shares) amounting to ₹2,49,600.
For HNI/NII investors, the minimum application size is 3 lots comprising 1,800 shares, requiring an investment of ₹3,74,400. Applications can be made in multiples of the prescribed lot size thereafter.
Minimum Lot Investment (Retail) | 2 Lots |
Maximum Lot Investment (Retail) | 2 Lots |
HNI (Min) | 3 Lots |
Avience Biomedicals IPO Allotment Status
Investors can check the Avience Biomedicals IPO allotment status once the basis of allotment is finalized. The allotment status can be verified through the official website of the IPO Registrar or the BSE/NSE website by entering details such as PAN number, application number, or DP/Client ID.
The direct links to check the allotment status on the Registrar's portal and the stock exchange website are provided below for investors' convenience.
BSE Website - BSE IPO allotment status
Promoters And Management of Avience Biomedicals Ltd.
Mr. Dharam Deo Choudhary
Mr. Ram Nagina Choudhary
Mr. Janardan Pal
Ms. Deepa Choudhary.
Pre-Issue Promoter Shareholding | 87.89% |
Post-Issue Promoter Shareholding | 64.59% |
IPO Lead Managers
Fintellectual Corporate Advisors Pvt. Ltd.
Dividend Policy
Avience Biomedicals Limited has not declared or paid any dividends during the last three financial years. The company has primarily retained its earnings to support business growth, expansion initiatives, working capital requirements, and operational needs.
Any future declaration of dividends will depend on factors such as profitability, cash flows, financial condition, capital expenditure plans, working capital requirements, and the discretion of the Board of Directors, subject to applicable laws and regulations.
Conclusion
Avience Biomedicals IPO offers investors an opportunity to participate in the growing biotechnology and in-vitro diagnostics (IVD) sector. The company benefits from a diversified product portfolio, expanding domestic and international presence, and a strong focus on diagnostic solutions for healthcare institutions.
The company has demonstrated healthy financial growth, improving profitability, strong return ratios, and manageable debt levels. However, investors should also consider risks such as intense industry competition, regulatory compliance requirements, dependence on key suppliers, and ongoing research and development expenses. Overall, the IPO may be suitable for investors seeking exposure to the healthcare and diagnostics industry with a moderate-to-high risk appetite.
To read the Prospectus of the Company, click the link to download the DRHP.
DISCLAIMER: This article is for educational and informational purposes only and should not be considered as investment, financial, or trading advice. It does not constitute a buy, sell, or hold recommendation for any security or IPO. Investors should conduct their own research and consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks.
For more information, contact: support@stockart.co.in
